Gevo, Inc. announced today that it has been issued a new patent, U.S. Patent No. 8,431,374 (‘374 Patent), covering the foundational methods for low-cost isobutanol production at commercially relevant titer, productivity, and yields.
“This is a milestone achievement toward our goal of making commercial isobutanol a reality,” said Brett Lund, Gevo’s executive vice president and general counsel. “Titer, productivity, and yield are three of the key metrics needed to sustain an economically viable process for isobutanol production. This patent broadly protects methods of producing isobutanol at economically viable levels. Prospective producers of isobutanol cannot achieve commercially viable production without access to our ‘374 Patent.”
“This patent significantly strengthens Gevo’s intellectual property position and reinforces our unmatched ability to obtain dramatic improvements in commercially-viable isobutanol production,” added Lund. “We will continue to take the steps necessary to protect and maintain the integrity of our industry-leading technology.”
This is the tenth U.S. patent granted to Gevo within its biocatalyst portfolio. Gevo’s patent portfolio includes more than 450 patents and patent applications.
Gevo is a leading renewable chemicals and next-generation biofuels company. Gevo’s patent-protected, capital-light business model converts existing ethanol plants into bio-refineries to make isobutanol. This versatile chemical can be directly integrated into existing chemical and fuel products to deliver environmental and economic benefits. Gevo has executed initial commercial-scale production runs at its isobutanol facility in Luverne, Minn., and has a marquee list of partners including Coca-Cola, Sasol, and LANXESS, among others. Gevo is committed to a sustainable bio-based economy that meets society’s needs for plentiful food and clean air and water.
Source: Gevo, Inc., press release, 2013-04-30.